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background: Primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) restores epicardial 
patency in the infarct related artery but suboptimal microvascular perfusion occurs in up to 70% of patients. This microvascular obstruction 
(MVO) is associated with adverse left ventricular (LV) remodeling and worse clinical outcomes, independent of infarct size (IS). Data on 
therapies for MVO is conflicting. We undertook a prospective randomized open label blinded endpoint trial, “The REperfusion Facilitated 
by LOcal adjunctive therapy in STEMI (REFLO-STEMI)” study, to assess whether intra-coronary (IC) high dose adenosine or sodium 
nitroprusside (SNP) impact on IS and MVO measured with cardiac magnetic resonance (CMR).
methods:  247 STEMI patients were randomized to receive IC adenosine 1-2 mg or SNP 250 μg pre- and post-stenting versus standard 
PPCI in four UK centers. CMR was undertaken 24-96 hours after revascularization in 200 patients to assess myocardial salvage, MVO and 
IS. Clinical follow-up was to a median of 6 months. The primary endpoint was IS (% LV mass) on CMR.
Results:  Baseline, angiographic and CMR results (prior to final data validation) are summarized in Table 1. The groups were well matched. 
There was no statistically significant difference in IS (p=0.26) or MVO (p=0.46) between groups although a reduced MACE rate was 
observed in group C compared to group A (p=0.029).
conclusion: IC adenosine and SNP appear not to influence IS nor MVO as measured by CMR.
 
